Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MRUS logo MRUS
Upturn stock ratingUpturn stock rating
MRUS logo

Merus BV (MRUS)

Upturn stock ratingUpturn stock rating
$52.33
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/08/2025: MRUS (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

17 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $90.2

1 Year Target Price $90.2

Analysts Price Target For last 52 week
$90.2 Target price
52w Low $33.19
Current$52.33
52w High $62.98

Analysis of Past Performance

Type Stock
Historic Profit 40.26%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/08/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.92B USD
Price to earnings Ratio -
1Y Target Price 90.2
Price to earnings Ratio -
1Y Target Price 90.2
Volume (30-day avg) 17
Beta 1.04
52 Weeks Range 33.19 - 62.98
Updated Date 07/8/2025
52 Weeks Range 33.19 - 62.98
Updated Date 07/8/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.16

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -285.94%

Management Effectiveness

Return on Assets (TTM) -30.61%
Return on Equity (TTM) -58.66%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3467517673
Price to Sales(TTM) 71.55
Enterprise Value 3467517673
Price to Sales(TTM) 71.55
Enterprise Value to Revenue 63.35
Enterprise Value to EBITDA -4.91
Shares Outstanding 74476704
Shares Floating 59561743
Shares Outstanding 74476704
Shares Floating 59561743
Percent Insiders 2.33
Percent Institutions 99.34

ai summary icon Upturn AI SWOT

Merus BV

stock logo

Company Overview

overview logo History and Background

Merus BV is a clinical-stage immuno-oncology company developing innovative full-length multi-specific antibodies, referred to as Biclonicsu00ae. Founded in 2003, the company has focused on developing therapies to treat cancer by harnessing the human immune system. Their Biclonicsu00ae technology platform allows for efficient discovery and development of antibody therapeutics.

business area logo Core Business Areas

  • Oncology Therapeutics: Focuses on developing multi-specific antibodies for the treatment of various cancers.
  • Biclonicsu00ae Platform: Development and optimization of the Biclonicsu00ae technology, a proprietary platform for generating full-length IgG multi-specific antibodies.
  • Research and Development: Continues to research and develop new therapeutic candidates and optimize existing ones.

leadership logo Leadership and Structure

The leadership team consists of a CEO, CFO, CSO, and other key executive positions. The company has a functional organizational structure with departments dedicated to research, development, clinical trials, and business operations.

Top Products and Market Share

overview logo Key Offerings

  • Zenocutuzumab: Zenocutuzumab is Merus' lead clinical candidate, a Biclonicsu00ae antibody targeting HER2 and HER3 for the treatment of NRG1 fusion-positive cancers. Phase 1/2 eNRGy trial ongoing. Competitors include companies developing targeted therapies against specific cancer mutations, such as Novartis and Roche. Market share is currently not established as the drug is in clinical development.
  • Petosemtamab: Petosemtamab is a Biclonicsu00ae antibody targeting EGFR and c-MET for the treatment of solid tumors. Phase 1/2 trial ongoing. Competitors include companies developing EGFR and c-MET inhibitors, such as Janssen Biotech and Eli Lilly. Market share is currently not established as the drug is in clinical development.

Market Dynamics

industry overview logo Industry Overview

The immuno-oncology market is experiencing rapid growth, driven by the development of novel therapies that harness the immune system to fight cancer. The multi-specific antibody segment is becoming increasingly competitive.

Positioning

Merus BV is positioned as a specialized player in the immuno-oncology field, leveraging its proprietary Biclonicsu00ae technology to develop differentiated multi-specific antibody therapeutics. They are focused on targeting specific cancer pathways and mutations.

Total Addressable Market (TAM)

The TAM for cancer therapies is estimated to be in the hundreds of billions of dollars. Merus is positioned to address a portion of this TAM by targeting specific cancer types with high unmet need, focusing on precision medicine.

Upturn SWOT Analysis

Strengths

  • Proprietary Biclonicsu00ae technology
  • Strong scientific expertise in multi-specific antibody development
  • Pipeline of clinical-stage immuno-oncology candidates
  • Strategic collaborations with pharmaceutical companies

Weaknesses

  • Reliance on clinical trial outcomes
  • Limited commercial infrastructure
  • High cash burn rate
  • Dependence on collaborations

Opportunities

  • Positive clinical trial results for lead candidates
  • Expansion of pipeline through new Biclonicsu00ae targets
  • Partnerships for commercialization
  • Acquisition by a larger pharmaceutical company

Threats

  • Clinical trial failures
  • Competition from other immuno-oncology companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • LLY
  • BMY

Competitive Landscape

Merus competes with large pharmaceutical companies in the immuno-oncology space. Its advantage lies in its proprietary Biclonicsu00ae technology, but it faces challenges in terms of resources and commercial infrastructure.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by the advancement of its clinical pipeline and strategic collaborations.

Future Projections: Future growth is dependent on clinical trial outcomes and potential commercialization of its lead candidates.

Recent Initiatives: Recent initiatives include advancing clinical trials for Zenocutuzumab and Petosemtamab and expanding collaborations with pharmaceutical partners.

Summary

Merus BV is a clinical-stage immuno-oncology company with a promising proprietary technology platform. Their clinical pipeline offers potential for significant growth if clinical trials are successful. However, they face challenges related to funding, competition, and regulatory hurdles. Collaborations are crucial for their continued development and potential commercial success. The company's future relies heavily on positive outcomes from its ongoing clinical trials.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Merus BV's official website
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Merus BV

Exchange NASDAQ
Headquaters -
IPO Launch date 2016-05-19
CEO, President & Executive Director Dr. Sven Ante Lundberg M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 260
Full time employees 260

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.